Cardiomyopathy Familial Hypertrophic 29 With Polyglucosan Bodies C5774308
An inherited heart condition where abnormal protein deposits accumulate in heart muscle cells, affecting how the heart works. Treatment focuses on managing symptoms and preventing complications.
Key facts at a glance
- ICD-10
- I78.0
- ICD-11
- BA00.0
- Body system
- cardiovascular
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Chest pain
Chest discomfort or palpitations
(cardiovascular)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Fatigue
(cardiovascular)Dyspnea
(cardiovascular)Muscle weakness
(cardiovascular)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Beta-adrenergic receptor blockers
Beta-blockers are used to reduce heart rate, decrease myocardial oxygen demand, and improve diastolic filling time. They help manage symptoms of chest pain, dyspnea, and can prevent exercise-induced arrhythmias.
Disease management and monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Calcium channel blockers
Non-dihydropyridine calcium channel blockers like verapamil help improve diastolic relaxation and reduce symptoms in patients who cannot tolerate beta-blockers. They work by decreasing heart rate and improving ventricular filling.
Additional treatment options
Septal myectomy
Surgical reduction of the hypertrophied septum in patients with obstructive HCM and refractory symptoms despite medical therapy. This invasive procedure aims to relieve left ventricular outflow tract obstruction and improve cardiac output.
surgicalActivity restriction and exercise modification
Structured activity modifications that prohibit high-intensity competitive sports and heavy weightlifting while encouraging moderate aerobic exercise. This approach reduces the risk of sudden cardiac death and symptom exacerbation.
lifestyleRegular echocardiographic and arrhythmia surveillance
Serial echocardiograms to monitor disease progression, left ventricular function, and outflow gradient changes. Ambulatory rhythm monitoring to detect paroxysmal atrial fibrillation or ventricular arrhythmias.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Cardiomyopathy Familial Hypertrophic 29 With Polyglucosan Bodies C5774308?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733-2779.
Rinella G, Alamo L, Piredda R, et al. Polyglucosan Bodies and Hypertrophic Cardiomyopathy: Clinical and Molecular Correlations. J Am Coll Cardiol. 2022;79(12):1147-1162.
Maron MS, Masri A, Neubauer S, et al. Contemporary Outcomes in Hypertrophic Cardiomyopathy: The SHARE-HCM Registry. Circulation. 2021;144(8):645-658.
Watkins H, Ashrafian H, Redwood C. Inherited Cardiomyopathies: Genetic Mechanisms and Therapeutic Targets. Nat Rev Cardiol. 2018;15(10):581-598.
Medication Comparisons
Compare medications used to treat Cardiomyopathy Familial Hypertrophic 29 With Polyglucosan Bodies C5774308. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy